CD44 and breast carcinoma: Although both GRP78 and CD44 have been widely implicated in aggressive cancer growth and therapeutic resistance, the physical and functional interactions of these two proteins in the context of breast cancer cells resistant to hormonal treatment are just emerging (Chiu et al, 2013; Tseng et al, 2019).